Abstract:5182 Bcl-2 family of proteins are over-expressed in many cancers including leukemia and lymphoma, and it’s now recognized that overexpression of Bcl-2 family proteins plays an important role in the resistance to current anti-cancer therapies and is associated with unfavorable outcome. Gossypol is a polyphenolic aldehyde occurring naturally in cottonseed that has been extensively investigated as a male contraceptive agent, was recently discovered as a potent pan inhibitor of Bcl-2 family proteins. To overcome the potential non-specific toxicity related to the two reactive aldehyde groups in gossypol, we designed and synthesized a novel apogossypolone (ApoG2) in which the two aldehyde groups of gossypol are completely removed. We showed previously that ApoG2 exhibited more potent binding to Bcl-2 proteins, with Ki value of 25 nM for Mcl-1, Ki value of 35 nM for Bcl-2, respectively. In this study, we compared the stability, tolerance and antiproliferation effects in four human leukemia and lymphoma cells (HL-60, U937, K562, and Raji). Each sample of stability tests was evaluated for spectral purity using a proposed HPLC method and an HPLC system equipped with UV detector. The results showed that ApoG2 is very stable in the solid states upon standing at room temperatures for at least three weeks, and in various vehicles such as CMC (carboxymethylcellulose), DMSO and sesame oil. More importantly, when gossypols and ApoG2 were subjected to stress conditions of acid, base, peroxide and light, ApoG2 is the only stable compound resistant to acid, base, peroxide and light among gossypol and gossypol derivatives. The cytotoxicity was assessed in cell cultures derived from leukaemia and lymphoma using the tetrazolium-based WST viability assay. ApoG2 induced a dose-dependent cell killing effect in all cell lines with a mean IC50 of 1-3 μM at 72 hours and was significantly more potent than the racemic gossypol. In vitro, ApoG2 also demonstrated strong synergy with various kinase inhibitors in multiple cancer cell lines. Furthermore, ApoG2 was investigated in both mice and rats for maximal tolerated dose (MTD), and the data indicate that ApoG2 was significantly more tolerable than gossypol with MTD dose at more than 2,000 mg/kg level in a multi-dosing schedule. Preliminary studies using one gastric cancer xenograft model showed that ApoG2 is orally active against tumor proliferation in vivo. These investigations suggest that a novel and potent derivative of gossypol without aldehyde functional groups such as ApoG2 may have therapeutic potential for human leukemia/lymphoma and solid tumors either as a single agent or in a combination regimen.

A Liposomal Delivery Vehicle for the Anticancer Agent Gossypol.

Cyclic RGD-Decorated Liposomal Gossypol AT-101 Targeting for Enhanced Antitumor Effect

Double-layered Hyaluronic Acid/stearic Acid-Modified Polyethyleneimine Nanoparticles Encapsulating (-)-gossypol: a Nanocarrier for Chiral Anticancer Drugs.

Gossypol with Hydrophobic Linear Esters Exhibits Enhanced Antitumor Activity As an Inhibitor of Antiapoptotic Proteins.

Natural Product Gossypol and Its Derivatives in Precision Cancer Medicine

A Novel Water-Soluble Gossypol Derivative Increases Chemotherapeutic Sensitivity and Promotes Growth Inhibition in Colon Cancer

PEGylated liposomes as delivery systems for Gambogenic acid: Characterization and in vitro/in vivo evaluation

Gossypol Has Anti-Cancer Effects by Dual Targeting Mdm2 and Vegf in Human Breast Cancer

The potential roles of gossypol as anticancer agent: advances and future directions

Pharmacokinetics, Biodistribution, and Bioavailability of Gossypol-Loaded Pluronic® F127 Nanoparticles

Antitumor activities of novel glycyrrhetinic acid-modified lipogel hybrid system in vitro

Synergistic cytotoxicity of Bcl-xL inhibitor, gossypol and chemotherapeutic agents in non-Hodgkin’s lymphoma cells

A Novel Pan Inhibitor of Bcl-2 and Mcl-1 Apogossypolone (apog2) with Superior Stability and Improved Activity Against Human Leukemia and Lymphoma Cells.

Preclinical Efficacy and Toxicity Analysis of the Pan-Histone Deacetylase Inhibitor Gossypol for the Therapy of Colorectal Cancer or Hepatocellular Carcinoma

Preparation of a novel nanoparticles of (-)-gossypol and growth inhibition on human prostate cancer PC-3 cells in vitro

A Wogonin-Loaded Glycyrrhetinic Acid-Modified Liposome for Hepatic Targeting with Anti-Tumor Effects.

TPGS-modified liposomes for the delivery of ginsenoside compound K against non-small cell lung cancer: formulation design and its evaluation in vitro and in vivo.

Development of Liposomal Ginsenoside Rg3: Formulation Optimization and Evaluation of Its Anticancer Effects

A Novel Saponin Liposomes Based on the Couplet Medicines of Platycodon Grandiflorum–glycyrrhiza Uralensis for Targeting Lung Cancer

Suppression of LPS-induced Inflammatory Responses by Gossypol in RAW 264.7 Cells and Mouse Models.

One Stone Four Birds: A Novel Liposomal Delivery System Multi-functionalized with Ginsenoside Rh2 for Tumor Targeting Therapy